NEW YORK (GenomeWeb News) – Norwegian biotech DiaGenic said it will use its gene expression technology to identify biomarkers of early-stage Alzheimer's disease for Pfizer, under a deal announced today by DiaGenic.
The firms will conduct a study, expected to begin this month, to compare longitudinal changes in blood-based gene expression patterns in patients with stable mild cognitive impairment, progressive MCI, and Alzheimer's disease. They hope to identify gene expression patterns in patients who progress from MCI to Alzheimer's disease and with different stages of the disease.
Pfizer will receive a non-exclusive, worldwide license for use of DiaGenic's MCI test and Alzheimer's test in its R&D development programs.
Additional terms of the deal were not disclosed.
In a statement, Erik Christensen, CEO of Oslo, Norway-based DiaGenic, said the deal "is the first result of DiaGenic's refocused strategy on teaming up with large pharmaceutical companies to deliver new diagnostic tools."